GeronFRA:GON -2.81%39 OCF Margin % is -121.35% as of Mar. 2026. GuruFocus rates FRA:GON with a GF Score™ of 39/100 and a GF Value™ of €6.00 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 958 Biotechnology companies, Geron ranks better than 50.21% on this metric.
OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Geron's Cash Flow from Operations for the
three
months ended in Mar. 2026 was €-54.4 Mil. Geron's Revenue for the
three
months ended in Mar. 2026 was €44.8 Mil. Therefore, Geron's OCF Margin % for the quarter that ended in Mar. 2026 was -121.35%.
The historical rank and industry rank for Geron's OCF Margin % or its related term are showing as below:
FRA:GON'
s OCF Margin % Range Over the Past 10 Years
Min: -70777.64 Med: -4415.28 Max: -60.39
Current: -64.41
During the past 13 years, the highest OCF Margin % of Geron was -60.39%. The lowest was -70777.64%. And the median was -4415.28%.
FRA:GON's OCF Margin % is ranked better than 50.21% of 958
companies
in the Biotechnology industry
Industry Median: -68.59
vs FRA:GON: -64.41
Geron OCF Margin % Related Terms
Geron OCF Margin % Historical Data
* Premium members only.
The historical data trend for Geron's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GON vs LBRX, ODTX, OMER: OCF Margin % Comparison
For the Biotechnology subindustry, Geron's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geron OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geron's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Geron's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geron (FRA:GON) has a OCF Margin % of -121.35% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Geron and its competitors. According to the industry distribution chart, Geron ranks #477 out of 958 companies in the Biotechnology industry, placing it in the top 49.8%.
Is Geron's OCF Margin % too high?
Geron's current OCF Margin % is -121.35%. Based on the distribution chart, Geron ranks #477 out of 958 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Geron has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's OCF Margin % compare to LBRX and ODTX?
According to the Biotechnology industry distribution chart, Geron ranks #477 out of 958 companies for OCF Margin %. This puts Geron in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Geron and its competitors. Geron's current OCF Margin % is -121.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (FRA:GON) is currently considered Possible Value Trap. The stock's GF Value™ is €6.00, compared to a current price of €1.18 — trading 80.4% below its estimated fair value. The current OCF Margin % is -121.35%. Geron's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Geron (FRA:GON), the current OCF Margin % is -121.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Geron (FRA:GON) Overvalued in 2026?
Based on GuruFocus' analysis, Geron stock appears to be undervalued.
The current stock price of €1.18 is trading 80.4% below its estimated GF Value™ of €6.00.
GuruFocus considers Geron to be Possible Value Trap.
Key valuation signals for FRA:GON:
OCF Margin %: -121.35%
GF Value™: €6.00 vs. price of €1.18 (80.4% below fair value)
No single metric tells the full story. See the FRA:GON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
39GF Score
Get the complete analysis for FRA:GON
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GON has been successfully added to your 
